Literature DB >> 27299459

Effect of EphB4/EphrinB2 reverse signal on angiogenesis induced by Xuefu Zhuyu Capsule () containing serum in human microvascular endothelial cell 1.

Jing-Si Zhang1, Yi-Zheng Wang2, Ya-Qiong Hu2, Fan Lin2, Dong Gao3, Jun Song4, Ted J Kaptchuk5, Ke-Ji Chen6.   

Abstract

OBJECTIVE: To evaluate the effect of Xuefu Zhuyu Capsule ()-containing serum (XFZY-CS) on EphB4/ephrinB2 and its reverse signal in human microvascular endothelial cell-1 (HMEC-1).
METHODS: XFZY-CS and the blank control serum were collected. HMEC-1 cells were randomly assigned to 6 groups including the concentration 1.25%, 2.5%, and 5% XFZY-CS groups and their blank serum control ones. The angiogenesis effect of XFZY-CS was tested with an in vitro tube formation assay and the best condition of pro-angiogenesis was determined. The effect of XFZY-CS on EphB4/ephrinB2 and the reverse signal were determined by Western blot and real-time quantitative polymerase chain reaction, respectively; we also confifirmed the results through activating and inhibiting the reverse signal by EphB4/fc and pyrophosphatase/ phosphodiesterase2 (PP2).
RESULTS: XFZY-CS promoted angiogenesis at the concentration of 2.5% corresponding serum after being cultured for 48 h, while inhibited angiogenesis at the concentration of 5% after culturing for 48 and 72 h. Under the 2.5% serum concentration, XFZY up-regulated the expression of EphB4-mRNA at 12 h (P<0.05), and down-regulates its expression at 24 h (P<0.01). Protein expression of EphB4 was apparently up-regulated at 12 h and down-regulated at 24 h. The phosphorylation of ephrinB2 increased at 9 h (P<0.05). In addition, 2.5% XFZY-CS played a similar role as the reverse signaling activator EphB4/Fc ranging from 0.5 to 5 μg/mL (P>0.05). XFZY-CS also reduced the inhibitive effect of PP2 in limited periods.
CONCLUSIONS: EphB4/ephrinB2 was the upstream signal in the process of angiogenesis and its reverse signaling was responsible for XFZY's effect on promoting angiogenesis.

Entities:  

Keywords:  Xuefu Zhuyu Capsule; angiogenesis; ephrinB2/EphB4 reverse signal

Mesh:

Substances:

Year:  2016        PMID: 27299459     DOI: 10.1007/s11655-016-2470-9

Source DB:  PubMed          Journal:  Chin J Integr Med        ISSN: 1672-0415            Impact factor:   1.978


  14 in total

Review 1.  'Eph'ective signaling: forward, reverse and crosstalk.

Authors:  Keith K Murai; Elena B Pasquale
Journal:  J Cell Sci       Date:  2003-07-15       Impact factor: 5.285

2.  A microarray analysis of angiogenesis modulation effect of Xuefu Zhuyu Decoction on endothelial cells.

Authors:  Jun Song; Wen-Yuan Chen; Li-Ya Wu; Liang-Pu Zheng; Wei Lin; Dong Gao; Ted J Kaptchuk; Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2012-07-07       Impact factor: 1.978

3.  Expression of ephrinB2 identifies a stable genetic difference between arterial and venous vascular smooth muscle as well as endothelial cells, and marks subsets of microvessels at sites of adult neovascularization.

Authors:  D Shin; G Garcia-Cardena; S Hayashi; S Gerety; T Asahara; G Stavrakis; J Isner; J Folkman; M A Gimbrone; D J Anderson
Journal:  Dev Biol       Date:  2001-02-15       Impact factor: 3.582

4.  Distinct roles of ephrin-B2 forward and EphB4 reverse signaling in endothelial cells.

Authors:  Koichi Hamada; Yuichi Oike; Yasuhiro Ito; Hiromitsu Maekawa; Keishi Miyata; Taizo Shimomura; Toshio Suda
Journal:  Arterioscler Thromb Vasc Biol       Date:  2003-02-01       Impact factor: 8.311

5.  Attenuation of ephrinB2 reverse signaling decreases vascularized area and preretinal vascular tuft formation in the murine model of oxygen-induced retinopathy.

Authors:  Alyssa C Taylor; Thomas A Mendel; Katelyn E Mason; Katherine E Degen; Paul A Yates; Shayn M Peirce
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-08-13       Impact factor: 4.799

6.  The effect of Xuefu Zhuyu Decoction on in vitro endothelial progenitor cell tube formation.

Authors:  Dong Gao; Li-ya Wu; Yu-huan Jiao; Wen-yuan Chen; Yan Chen; Ted J Kaptchuk; Bo Lu; Jun Song; Ke-ji Chen
Journal:  Chin J Integr Med       Date:  2010-02-04       Impact factor: 1.978

7.  Roles of ephrinB ligands and EphB receptors in cardiovascular development: demarcation of arterial/venous domains, vascular morphogenesis, and sprouting angiogenesis.

Authors:  R H Adams; G A Wilkinson; C Weiss; F Diella; N W Gale; U Deutsch; W Risau; R Klein
Journal:  Genes Dev       Date:  1999-02-01       Impact factor: 11.361

8.  EphrinB2 reverse signaling protects against capillary rarefaction and fibrosis after kidney injury.

Authors:  Yujiro Kida; Nicholas Ieronimakis; Claudia Schrimpf; Morayma Reyes; Jeremy S Duffield
Journal:  J Am Soc Nephrol       Date:  2013-03-14       Impact factor: 10.121

9.  Ephrin-B2 selectively marks arterial vessels and neovascularization sites in the adult, with expression in both endothelial and smooth-muscle cells.

Authors:  N W Gale; P Baluk; L Pan; M Kwan; J Holash; T M DeChiara; D M McDonald; G D Yancopoulos
Journal:  Dev Biol       Date:  2001-02-15       Impact factor: 3.582

10.  Molecular distinction and angiogenic interaction between embryonic arteries and veins revealed by ephrin-B2 and its receptor Eph-B4.

Authors:  H U Wang; Z F Chen; D J Anderson
Journal:  Cell       Date:  1998-05-29       Impact factor: 41.582

View more
  3 in total

1.  Effect of Xuefu Zhuyu Capsule () on Angiogenesis in Hindlimb Ischemic Rats.

Authors:  Wei-Li Shi; Peng-Fei Lu; Dong Gao; Jun Song; Ke-Ji Chen
Journal:  Chin J Integr Med       Date:  2019-03-27       Impact factor: 1.978

2.  Combination of Ligusticum Chuanxiong and Radix Paeonia Promotes Angiogenesis in Ischemic Myocardium through Notch Signalling and Mobilization of Stem Cells.

Authors:  Wei-Li Shi; Jun Zhao; Rong Yuan; Yan Lu; Qi-Qi Xin; Yu Liu; Wei-Hong Cong; Ke-Ji Chen
Journal:  Evid Based Complement Alternat Med       Date:  2019-02-17       Impact factor: 2.629

Review 3.  Efficacy and Safety of Xue-Fu-Zhu-Yu Decoction for Patients with Coronary Heart Disease: A Systematic Review and Meta-Analysis.

Authors:  Shuo Zhang; Zhen-Lin Chen; Yu-Ping Tang; Jin-Long Duan; Kui-Wu Yao
Journal:  Evid Based Complement Alternat Med       Date:  2021-09-29       Impact factor: 2.629

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.